The core conflict in mycoplasma testing is time versus compliance: culture methods take too long, and rapid methods were feared until regulators couldn't be convinced. The MycAway™ 2G kit resolves both.
The Hidden Risk Nobody Talks About
Mycoplasma are the smallest prokaryotes (0.1–0.3 µm), wall-less organisms that slip through standard sterilizing filters and never cloud your culture medium. Instead, they quietly siphon nutrients, reprogram cell metabolism, and suppress gene expression and viral titers—the leading contamination threat in cell-based biologics. Reported contamination rates in cell culture run as high as 5–35%, and most infections are asymptomatic until the damage is done.
The quality impact is measurable. In a controlled CHO bioreactor inoculation study, a mycoplasma event significantly altered key quality attributes of the monoclonal antibody product. This isn't just a "contamination" problem—it's a direct hit on CQAs, regulatory filings, and clinical safety.
The real conflict, however, is temporal. The compendial culture method requires 28 days of incubation and observation. Cell and gene therapy (CGT) autologous products often have shelf lives measured in hours—commonly 48–72 hours, and as short as 12 hours for fresh formulations. China's Technical Guidelines for Pharmaceutical Research and Evaluation of Immune Cell Therapy Products (Trial) explicitly requires mycoplasma testing at critical process time points and as a final release test, while adding: "If compendial methods cannot meet the requirement, novel testing methods may be developed for release—provided they are fully validated[1] ." That clause—the compendia's green light for validated nucleic acid amplification technology (NAT)—is exactly where MycAway™ 2G begins.
Compliance Confidence—One Validation, Aligned with Global Compendia
In the regulatory world, mycoplasma testing isn't "if you can detect it, you're done." Whether the method itself is accepted by compendia and regulators is the prerequisite for release authority.
|
Regulation / guidance |
Mycoplasma testing requirement |
Position on NAT |
Conformance of this kit |
|
ChP 3301 [2] |
Culture method + indicator cell method; mandatory for MCB/WCB/EOPC |
Allows "other methods recognized by the national control authority" |
Complete validation data + NIFDC joint study [9] |
|
EP 2.6.7 (12.2) [3] |
Culture / indicator cell methods as the baseline |
NAT established as equivalent after validation, LOD ≤ 10 CFU/mL |
10 strains, 24/24 at ≤ 10 CFU/mL |
|
JP G3-14-170 [4] |
Harmonized with EP 2.6.7 |
NAT may substitute after validation with sensitivity not inferior to culture |
Validated under the same EP framework |
|
USP <63> [5] |
Recommended mycoplasma test methods |
NAT applicable after validation |
Validated under the same EP framework |
|
ICH Q5A(R2) [6] |
Control of adventitious agents including mycoplasma |
Explicitly endorses molecular tests such as PCR for rapid, sensitive detection |
Coverage meets testing needs |
|
CDE 2022 guidance [1] |
In-process testing at critical time points + final product release |
"Where compendial methods cannot deliver, new methods may be developed for release with full validation" |
Class 1 IND evidence [7] |
|
FDA cell substrate guidance [8] |
Control of raw materials, virus seeds and harvest fluids |
Recognizes validated rapid methods |
Covers the full QC chain |
▮ The compliance path for NAT replacing culture (five steps)
› Manufacturer method validation: specificity / detection limit / robustness validated under the EP framework — Yeasen has delivered the complete report.
› User suitability verification: validate detection limit / specificity / robustness / reproducibility on your own sample matrices per ChP 9201.
› Comparison with culture: per EP, test reference standards in parallel for CFU and GC to confirm sensitivity not inferior to culture.
› Anti-false-negative QC: Built-in CY5 internal control (IC) monitors the entire run; if the target fails to amplify while IC is suppressed, the system calls "indeterminate"—never a reckless release
› Regulatory communication & release — Align the method substitution with regulators, write it into your SOP, and embed it in GMP release testing
All 10 Compendial Strains Detected—Sensitivity Down to 0.1 CFU/mL, Far Beyond the Compendial Threshold
1. Hard detection-limit benchmarks strictly per EP 2.6.7
Using commercial mycoplasma sensitivity standards (Minerva Biolabs 10CFU™, derived from UK NCTC reference strains), LOD validation covered the 10 strains required by EP 2.6.7 and JP G3-14-170. Each strain was tested in parallel 24 times at 10 CFU/mL: 24/24 positive across all 10 strains (compendial requirement: ≥23/24, i.e., ≥95% detection). The actual LOD ranged from 0.1–2 CFU/mL—5 to 100× below the compendial 10 CFU/mL line.
All 10 pharmacopeial strains positive in 24/24 replicates at 10 CFU/mL; practical detection limits 0.1–2 CFU/mL — fully beyond the pharmacopeial threshold.
2. ≥183 Mollicutes Fully Covered, Zero Cross-Reactivity
▮ Covering 133 Mycoplasma + 9 Ureaplasma + 34 Spiroplasma + 7 Acholeplasma and more
The kit's primers and probe are designed on highly conserved 16S rRNA sequences, covering ≥183 mollicutes DNA sequences (133 Mycoplasma + 9 Ureaplasma + 34 Spiroplasma + 7 Acholeplasma and others) — comprehensively covering the strain types that EP/JP/USP/WHO/ChP require for validation. Specificity validation was equally "zero cross-reactivity":
› Sample matrix interference: nine common media (DMEM, Ham's F-10, M-199, RPMI-1640, McCoy's 5A, Ham's F-12K, etc.) plus DNA diluent and their spiked samples — all matrices negative, all spikes positive, no interference.
› Cross-reactivity (strains): all 14 non-mollicute strains tested (Clostridium, Lactobacillus, Streptococcus, etc.) were negative — no cross-reactivity.
› Cross-reactivity (engineered cells): genomic DNA from HEK293, 293T, Vero, CHO, SF9 and other common engineered cell lines all negative — no cross-reactivity.
3. 100% Concordance with Culture—3 Hours Replacing 28 Days
▮ NAT results stand up to side-by-side comparison with culture
Regulators ask one question above all: do the results match? Using Mycoplasma orale (one of the most common cell-culture contaminants), NAT (40619ES + 18461ES pretreatment) was run head-to-head against all four compendial media (mycoplasma broth, arginine mycoplasma broth, mycoplasma semisolid, arginine mycoplasma semisolid):
|
Sample |
NAT (qPCR) |
Compendial culture (4 media) |
Agreement |
|
Mycoplasma, undiluted (Ct 35.71) |
Positive |
Positive in all 4 media (heavy growth) |
Consistent |
|
2-fold dilution (Ct 37.07) |
Positive |
Positive in all 4 media (light growth) |
Consistent |
|
Negative sample (blank medium) |
Negative (No Ct) |
No mycoplasma growth in any of the 4 media |
Consistent |
Overall concordance: 100%—and lower Ct values tracked with heavier culture growth. The NAT method compresses the testing cycle from 28 days to under 3 hours: precisely the "fully validated novel method" the CDE 2022 guideline encourages [1].
4. National-Level Endorsement—NIFDC-Led Publication in Molecules (May 2026)
A joint study led by the National Institutes for Food and Drug Control (NIFDC) with deep participation by Yeasen Biotechnology was published in Molecules in May 2026 [9]. NIFDC anchored the work from the national drug-quality-regulatory perspective—method compliance, universality, and evaluation criteria—while Yeasen contributed core enzyme raw materials, the reagent system, and extensive hands-on validation data. Together the teams built and systematically validated the complete NAT methodology for mycoplasma detection in biologics: specificity, sensitivity, reproducibility, and interference resistance.
The publication provides authoritative technical guidance for pharma companies, CDMOs, and testing labs building compliant platforms—and confirms that domestically produced molecular reagents can meet the exacting standards of national-level QC research. It's a landmark step toward breaking "import dependence" for high-end quality-control reagents.
The NIFDC-led joint study, published in MDPI Molecules (2026;31(11):1794).
5. Filing Evidence: Supporting a Class 1 Innovative Drug to a CDE IND
▮ A real filing case is more persuasive than any pitch
From cell bank characterization to IND submission, QC test items must withstand CDE scrutiny—and the same framework supports antibody drugs, vaccines, viral vectors, and cell therapy pipelines.
Case study: Shenzhen Huishan Biotech's Class 1 innovative drug HS SW01 cell injection (human umbilical cord–derived mesenchymal stem cells; indications: ankylosing spondylitis and systemic sclerosis). Mycoplasma testing was performed with the MycAway™ Mycoplasma qPCR Detection Kit (Probe Method, 2G), Cat. #40619ES. The program received CDE IND approval on October 12, 2025 (acceptance no. CXSL2500598), and multicenter Phase I/II trials are now registered on ClinicalTrials.gov (ankylosing spondylitis: NCT07534644; systemic sclerosis: NCT07535931) [7].
Beyond this case, the kit has supported other client pipelines through CDE IND approval (unnamed for confidentiality), with additional filings in progress.
From Pharmacopeial Compliance to IND Evidence — the MycAway™ 2G Answer to Mycoplasma Detection
▮ From probe-based design to compliant rollout, in one pass
- Multiplex probe qPCR with a safeguard at every step
MycAway™ 2G uses multiplex qPCR with dual hydrolysis probes: FAM channel detects the mycoplasma target; CY5 channel detects the internal control (IC). Dual-channel cross-interpretation structurally eliminates false negatives.
- Applications: one kit for every mycoplasma control point in biologics production
Suitable for rapid qualitative detection of potential mycoplasma contamination in production raw materials, cell banks, virus seeds, viral or cell harvests, and therapeutic cells—covering every critical control point required by global compendia and ICH Q5A(R2):
- End-to-End solution: pretreatment → extraction → detection
Manual extraction fits routine QC labs; the automated workflow scales to commercial manufacturing—one system from R&D through commercialization, with no method change and no broken data chain.
Using it compliantly: validate first, release second
Cite the manufacturer's validation data: Yeasen provides complete EP 2.6.7–framework validation reports and audit-ready documentation
Complete your own suitability validation on your matrices per ChP <9201>, including LOD, specificity, robustness, and culture-method comparison
Use as intended: for GMP release testing, add IC before extraction; discuss any method substitution with your regulator
"Rather miss than miscall—validate before you release" is the foundation of NAT's long-term regulatory acceptance. MycAway™ 2G delivers the validated data substrate so your suitability work starts from a reliable baseline and your filings stand on compliant ground.
Key specifications
|
Item |
Parameter |
|
Cat. No. / size |
40619ES25 (25T) | 40619ES60 (100T) |
|
Methodology |
Multiplex probe qPCR (TaqMan); FAM target + CY5 internal control (IC) |
|
Coverage |
≥183 mollicutes DNA (120 Mycoplasma + 9 Ureaplasma + 33 Spiroplasma + 7 Acholeplasma, etc.) |
|
Detection limit |
Meets the ≤10 CFU/mL pharmacopeial requirement (some strains down to 1 CFU/mL or below) |
|
Cycling program |
95 °C 5 min; 45 cycles (95 °C 15 s → 62 °C 30 s) |
|
Instruments |
ABI 7500, QuantStudio™ 5, SLAN-96S, Roche LightCycler® 480 |
|
Storage / shelf life |
-25 to -15°C, 24 months; tolerates 20 freeze–thaw cycles |
|
Quality system |
Manufactured under ISO 13485; complete validation report and audit documentation available |
As with any NAT method, users must still complete suitability validation in their own labs and align with regulators before release use—the universal precondition for any NAT substitution accepted by the compendia. What MycAway™ 2G delivers is a validated data floor: a reliable starting point for your validation, and a compliant basis for release and filing.
Product List
|
Product name |
Cat. No. |
Size |
|
Magnetic-Bead Residual DNA Sample Pre-treatment Kit (bottled) |
18461ES |
25T / 100T |
|
80511ES |
1 unit |
|
|
40619ES |
25T / 100T |
References
[1] NMPA Center for Drug Evaluation. Technical Guidelines for Pharmaceutical Research and Evaluation of Immunocyte Therapy Products (Trial), Notice No. 30 of 2022, May 2022.
[2] Mycoplasma Testing <3301>. Chinese Pharmacopoeia, 2025 Edition, Volume III, 3301.
[3] Mycoplasmas. European Pharmacopoeia, 12th Edition, Section 2.6.7 (12.2, NAT equivalence).
[4] Mycoplasma Testing for Cell Substrates. The Japanese Pharmacopoeia, 18th Edition, 2021: 2678–2682.
[5] <63> Mycoplasma Tests. United States Pharmacopeia.
[6] ICH Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.
[7] ClinicalTrials.gov: NCT07534644 (HS_SW01 Cells Injection, Shenzhen Huishan Biotechnology).
[8] FDA. Guidance for Industry: Characterization and Qualification of Cell Substrates and Cell Cultures Used in the Production of Viral Vaccines.
[9] Guo Y, Qin X, Zhang J, et al. Establishment of Nucleic Acid Amplification Technology for the Detection of Mycoplasma in Biological Products. Molecules. 2026;31(11):1794. doi:10.3390/molecules31111794.